Breadcrumb Home Studies Studies Search Filter Research Area All Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 15 studies. IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling P1110: Safety and PK of RAL in Neonates DAIDS Number 11891 Research Area Treatment Study Status Concluded P1101: Phase I/II Dose-Finding, Safety, Tolerance and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-infected and TB Co-infected Infants and Children DAIDS Number 11831 Research Area Treatment Study Status Concluded P1097: Raltegravir PK Study DAIDS Number 11790 Research Area Treatment Study Status Concluded P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded P1053: Evaluation PI-Containing vs. Non-PI-Containing Salvage Regimens. DAIDS Number 10131 Research Area Other Study Status Concluded Pagination Current page 1 Page 2 Next page Next
IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling
P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling
P1110: Safety and PK of RAL in Neonates DAIDS Number 11891 Research Area Treatment Study Status Concluded
P1101: Phase I/II Dose-Finding, Safety, Tolerance and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-infected and TB Co-infected Infants and Children DAIDS Number 11831 Research Area Treatment Study Status Concluded
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics
P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded
P1053: Evaluation PI-Containing vs. Non-PI-Containing Salvage Regimens. DAIDS Number 10131 Research Area Other Study Status Concluded
